Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from DPP-4 inhibitor to tirzepatide in hemodialysis patients with type 2 diabetes
jRCT1071260095Recruiting
- Sponsor
- Nagasaki Medical Association
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Nagasaki Medical Association. Primary endpoint: Time in range. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1071260095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071260095.